ana luisa rodrigues toste de carvalho

Dr. ana luisa rodrigues toste de carvalho

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
ACana luisa rodrigues toste de carvalho
ana luisa rodrigues toste de carvalho
HLHsiao-Yun Liu
Hsiao-Yun Liu
YCYa-Wen Chen
Ya-Wen Chen
MPMatteo Porotto
Matteo Porotto
AMAnne Moscona
Anne Moscona
HSHans-Willem Snoeck
Hans-Willem Snoeck

Verified
Journal Article
Open access
PDF file
RFRaquel Fernandes
Raquel Fernandes
CBCatarina Barbosa-Matos
Catarina Barbosa-Matos
CPCaroline Borges Pereira
Caroline Borges Pereira
ACana luisa rodrigues toste de carvalho
ana luisa rodrigues toste de carvalho
SCSandra Costa
Sandra Costa
Acute respiratory distress syndrome (ARDS) is a life-threatening lung injury that currently lacks effective clinical treatments. Evidence highlights the potential role of glycogen synthase kinase-3 (GSK-3) inhibition in mitigating severe inflammation. The inhibition of GSK-3α/β by CHIR99021 promoted fetal lung progenitor proliferation and maturation of alveolar epithelial cells (AECs). The precise impact of CHIR99021 in lung repair and regeneration during acute lung injury (ALI) remains unexplored. This study intends to elucidate the influence of CHIR99021 on AEC behaviour during the peak of the inflammatory phase of ALI and, after its attenuation, during the repair and regeneration stage. Furthermore, a long-term evaluation was conducted post CHIR99021 treatment at a late phase of the disease. Our results disclosed the role of GSK-3α/β inhibition in promoting AECI and AECII proliferation. Later administration of CHIR99021 during ALI progression contributed to the transdifferentiation of AECII into AECI and an AECI/AECII increase, suggesting its contribution to the renewal of the alveolar epithelial population and lung regeneration. This effect was confirmed to be maintained histologically in the long term. These findings underscore the potential of targeted therapies that modulate GSK-3α/β inhibition, offering innovative approaches for managing acute lung diseases, mostly in later stages where no treatment is available.

13 February 2026 in Practical Neurology
Verified
Journal Article
Closed access
ACana luisa rodrigues toste de carvalho
ana luisa rodrigues toste de carvalho
CGCarlos Grijó
Carlos Grijó
CFCatarina Faustino
Catarina Faustino
DFDaniela Ferro
Daniela Ferro
GSGabriela Sousa
Gabriela Sousa
MPMariana Pintalhão
Mariana Pintalhão
Serotonin syndrome is a life-threatening adverse drug reaction caused by excessive serotonergic activity from therapeutic use, overdose or drug interactions. Its recognition is challenging, as manifestations range from subtle to severe and fatal. Key diagnostic features are autonomic dysfunction, motor hyperactivity and exaggerated reflexes, including clonus. We report a young woman with severe serotonin syndrome due to serotonergic polypharmacy who developed reversible cerebral vasoconstriction syndrome and overlapping posterior reversible encephalopathy syndrome. The diagnosis was initially delayed because attention had focused on her prominent vascular features with severe focal neurological deficits rather than the underlying toxidrome. We diagnosed serotonin syndrome as she developed more characteristic features. This case highlights the importance of considering serotonin syndrome in patients receiving serotonergic medications who develop motor findings, autonomic dysfunction or unexplained neurological deterioration.